CN101312733A - 戊酸雌二醇或雌二醇与地诺孕素组合以口服避孕药形式口服治疗功能失调性子宫出血的用途 - Google Patents

戊酸雌二醇或雌二醇与地诺孕素组合以口服避孕药形式口服治疗功能失调性子宫出血的用途 Download PDF

Info

Publication number
CN101312733A
CN101312733A CNA2006800381810A CN200680038181A CN101312733A CN 101312733 A CN101312733 A CN 101312733A CN A2006800381810 A CNA2006800381810 A CN A2006800381810A CN 200680038181 A CN200680038181 A CN 200680038181A CN 101312733 A CN101312733 A CN 101312733A
Authority
CN
China
Prior art keywords
estradiol
dienogest
combination
daily dosage
dosage units
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800381810A
Other languages
English (en)
Chinese (zh)
Inventor
S·宙恩
P·布德
J·昂德里卡
A·塞西
H·齐默尔曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35811580&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101312733(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering AG filed Critical Schering AG
Publication of CN101312733A publication Critical patent/CN101312733A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CNA2006800381810A 2005-10-13 2006-10-12 戊酸雌二醇或雌二醇与地诺孕素组合以口服避孕药形式口服治疗功能失调性子宫出血的用途 Pending CN101312733A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05022324A EP1787649B1 (de) 2005-10-13 2005-10-13 Verwendung von Estradiolvalerat in Kombination mit Dienogest zur oralen Therapie der dysfunktionellen uterinen Blutung in Einheit mit einer oralen Kontrazeption
EP05022324.7 2005-10-13

Publications (1)

Publication Number Publication Date
CN101312733A true CN101312733A (zh) 2008-11-26

Family

ID=35811580

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800381810A Pending CN101312733A (zh) 2005-10-13 2006-10-12 戊酸雌二醇或雌二醇与地诺孕素组合以口服避孕药形式口服治疗功能失调性子宫出血的用途

Country Status (22)

Country Link
EP (2) EP1787649B1 (https=)
JP (2) JP5735200B2 (https=)
KR (2) KR101218872B1 (https=)
CN (1) CN101312733A (https=)
AR (1) AR056694A1 (https=)
AT (2) ATE424828T1 (https=)
CA (1) CA2623024C (https=)
CL (1) CL2011000283A1 (https=)
CY (2) CY1110321T1 (https=)
DE (2) DE502005006837D1 (https=)
DK (2) DK1787649T3 (https=)
DO (1) DOP2006000221A (https=)
ES (2) ES2322479T3 (https=)
HR (1) HRP20090256T1 (https=)
ME (1) ME01056B (https=)
PE (2) PE20100090A1 (https=)
PL (2) PL1787649T3 (https=)
PT (2) PT1787649E (https=)
SI (2) SI1787649T1 (https=)
TW (2) TWI328453B (https=)
UY (1) UY29861A1 (https=)
WO (1) WO2007042296A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004019743B4 (de) 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
SI1787649T1 (sl) * 2005-10-13 2009-08-31 Bayer Schering Pharma Ag Uporaba estradiolvalerata v kombinaciji z dienogestom za oralno terapijo disfunkcionalne maternične krvavitve skupaj z oralno kontracepcijo
US8153616B2 (en) 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
EP1930010A1 (de) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4429374C1 (de) * 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
DE19540253C2 (de) * 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
ATE249222T1 (de) * 1996-07-26 2003-09-15 Wyeth Corp Biphasische orale verhuetungsmethode und kit die eine kombination von progestin und eines oestrogens enthalten
US6251956B1 (en) 1998-08-20 2001-06-26 Ortho Pharmaceutical Corporation Combination progestin oral contraceptive regimen
EP1462106A1 (en) * 2003-03-28 2004-09-29 Pantarhei Bioscience B.V. Pharmaceutical compositions and kits comprising 17-beta-estradiol and a progesteron for the treatment of gynecological disorders
DE102004019743B4 (de) * 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
SI1787649T1 (sl) * 2005-10-13 2009-08-31 Bayer Schering Pharma Ag Uporaba estradiolvalerata v kombinaciji z dienogestom za oralno terapijo disfunkcionalne maternične krvavitve skupaj z oralno kontracepcijo

Also Published As

Publication number Publication date
CA2623024A1 (en) 2007-04-19
EP1933843A1 (de) 2008-06-25
ES2322479T3 (es) 2009-06-22
WO2007042296A1 (de) 2007-04-19
ATE424828T1 (de) 2009-03-15
JP5735200B2 (ja) 2015-06-17
JP2009511526A (ja) 2009-03-19
SI1933843T1 (sl) 2011-06-30
PT1787649E (pt) 2009-05-08
EP1787649A1 (de) 2007-05-23
ES2360302T3 (es) 2011-06-02
CL2011000283A1 (es) 2011-07-08
PT1933843E (pt) 2011-04-29
KR20080065651A (ko) 2008-07-14
HRP20090256T1 (en) 2009-06-30
AR056694A1 (es) 2007-10-17
DE502005006837D1 (de) 2009-04-23
PL1933843T3 (pl) 2011-06-30
SI1787649T1 (sl) 2009-08-31
CA2623024C (en) 2012-03-06
TW200731977A (en) 2007-09-01
DOP2006000221A (es) 2007-08-31
PE20100090A1 (es) 2010-03-12
DK1787649T3 (da) 2009-06-02
TWI328453B (en) 2010-08-11
UY29861A1 (es) 2007-05-31
DE502006008853D1 (de) 2011-03-17
EP1787649B1 (de) 2009-03-11
TW200829255A (en) 2008-07-16
ATE497387T1 (de) 2011-02-15
CY1111406T1 (el) 2015-08-05
KR20100082389A (ko) 2010-07-16
PL1787649T3 (pl) 2009-08-31
KR101218872B1 (ko) 2013-01-07
CY1110321T1 (el) 2015-01-14
DK1933843T3 (da) 2011-04-18
PE20070555A1 (es) 2007-07-12
JP2013047269A (ja) 2013-03-07
ME01056B (me) 2012-10-20
EP1933843B1 (de) 2011-02-02

Similar Documents

Publication Publication Date Title
JP7177313B2 (ja) 避妊用組成物および避妊方法
FI117850B (fi) Progesteroniantagonisteja lääkeaineiden valmistamiseksi, jotka on tarkoitettu kohdun toimintahäiriöistä johtuvien verenvuotojen hoitamiseksi
ES2202498T3 (es) Estuche para la contracepcion en mamiferos hembras, que consta de una combinacion de un agente gestageno y un agente estrogeno.
Erkkola et al. Role of progestins in contraception
KR102780201B1 (ko) 월경통 및 생리통의 관리방법
JP2007512291A (ja) ２種のエストロゲン及び／又はプロゲスチン組成物を含んで成る、２１〜２８日よりも長い期間にわたっての連続ホルモン処理のための医薬製剤
KR20150058555A (ko) 연장된 호르몬성 피임제 투약법에서 파탄성 출혈의 관리
KR20090080989A (ko) 여성 리비도의 유지 및/또는 증가를 위한 경구 치료요법을 위한 디에노게스트와 조합된 에스트라디올 발레레이트 또는 17β-에스트라디올의 용도
KR20010081087A (ko) 3 단계 경구 피임제
LaGuardia et al. Suppression of estrogen-withdrawal headache with extended transdermal contraception
ZA200404249B (en) Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
Verhoeven et al. The contraceptive vaginal ring, NuvaRing®, and antimycotic co-medication
AU759925B2 (en) Oral contraceptive preparation having a first phase comprising progestin/estrogen and a second phase comprising progestin
JP2013047269A (ja) 経口避妊薬の形での機能不全子宮出血の経口治療のためへの吉草酸エストラジオール又はエストラジオールとジエノゲストとの使用
US20100190757A1 (en) Combination preparation for oral contreaception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
CN1186023C (zh) 双相避孕方法及包含孕激素和雌激素组合物的药剂盒
Calhoun et al. Hormonal therapies for menstrual migraine
JPH0635388B2 (ja) 周閉経期、閉経期および閉経期後の障害をホルモン的に治療する医薬品組成物
Ziaei et al. Comparative study and evaluation of side effects of low-dose contraceptive pills administered by the oral and vaginal route
HK1124267A (en) Use of estradiol valerate or estradiol combined with dienogest for the oral therapy of dysfunctional uterine bleeding in the form of oral contraceptives
US20070088011A1 (en) Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
ES2382459T3 (es) Utilización de valerato de estradiol, en combinación con dienogest para la terapia por vía oral de la hemorragia uterina disfuncional, en unión con una contracepción oral
US20070088010A1 (en) Method of making a single-stage pharmaceutical preparation for oral therapy of dysfunctional uterine bleeding, containing ethinyl estradiol and dienogest
RS50849B (sr) Upotreba estradiolvalerata i dienogesta za oralno lečenje disfunkcionalnog uterinog krvarenja u kontracepcijskom metodu
CN1172675C (zh) 黄体酮拮抗剂用于制备治疗机能障碍性子宫出血的药物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1124267

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20081126

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1124267

Country of ref document: HK